scholarly journals Medical food development by dietetic management of the endocannabinoid system through dietary sources of β-caryophyllene

2021 ◽  
pp. 1-9
Author(s):  
Victor Chiruta
Keyword(s):  
Human Body ◽  
Inflammatory Markers ◽  
Endocannabinoid System ◽  
Full Potential ◽  
Biological Impact ◽  
Medical Food ◽  
Medical Foods ◽  
Stress Susceptibility ◽  
Insight Into

Objective: To research the biological impact on the endocannabinoid system (ECS) from dietary sources of [Formula: see text]-caryophyllene (BCP). This will encompass pre-clinical and clinical research for BCP. The bioavailability of BCP will be explored, focusing on bioavailability improvement. This research will establish if there is justification to warrant the development of a medical food for supporting the ECS through dietetic supplementation of BCP. Methods: Research and review papers were identified through the search engines Google Scholar, PubMed, and ScienceDirect. Main keywords included [Formula: see text]-caryophyllene, endocannabinoid system, dietary cannabinoids, cannabinoid type-2 receptor, and bioavailability. Results: The human body is limited in the digestion of BCP from food. This is because BCP is poorly absorbed in the gut. Everyone has different underlying endocannabinoid efficiency and most people do not have the full potential of supporting their ECS through diet. Conclusion: A medical food can be developed to use BCP with a delivery system, so that the bioactive food cannabinoid is readily absorbed. This will deliver dietary support to the ECS, that otherwise would be available from food. This review provides insight into the efficacy of using BCP in medical foods as dietary support for the ECS. Supporting the ECS can assist in maintaining homeostasis, regulating immune function, pain intensity, inflammatory markers, sleep patterns, mood, appetite, and stress susceptibility.

scholarly journals Endocannabinoids in neuroendopsychology: multiphasic control of mitochondrial function

2012 ◽  
Vol 367 (1607) ◽  
pp. 3342-3352 ◽  
Author(s):  
Alistair Nunn ◽  
Geoffrey Guy ◽  
Jimmy D. Bell
Keyword(s):  
Mitochondrial Function ◽  
Metabolic Pathways ◽  
Endocannabinoid System ◽  
Positive Energy ◽  
Positive Energy Balance ◽  
The Central Nervous System ◽  
Health And Disease ◽  
Insight Into ◽  
Subsequent Identification

The endocannabinoid system (ECS) is a construct based on the discovery of receptors that are modulated by the plant compound tetrahydrocannabinol and the subsequent identification of a family of nascent ligands, the ‘endocannabinoids’. The function of the ECS is thus defined by modulation of these receptors—in particular, by two of the best-described ligands (2-arachidonyl glycerol and anandamide), and by their metabolic pathways. Endocannabinoids are released by cell stress, and promote both cell survival and death according to concentration. The ECS appears to shift the immune system towards a type 2 response, while maintaining a positive energy balance and reducing anxiety. It may therefore be important in resolution of injury and inflammation. Data suggest that the ECS could potentially modulate mitochondrial function by several different pathways; this may help explain its actions in the central nervous system. Dose-related control of mitochondrial function could therefore provide an insight into its role in health and disease, and why it might have its own pathology, and possibly, new therapeutic directions.

Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players

2020 ◽  
Vol 26 ◽  
Author(s):  
Emir Muzurović ◽  
Zoja Stanković ◽  
Zlata Kovačević ◽  
Benida Šahmanović Škrijelj ◽  
Dimitri P Mikhailidis
Keyword(s):  
Diabetes Mellitus ◽  
Inflammatory Markers ◽  
High Specificity ◽  
Future Directions ◽  
Effective Strategies ◽  
Advantages And Disadvantages ◽  
Type 2 Dm ◽  
Increased Risk ◽  
Made In

: Diabetes mellitus (DM) is a chronic and complex metabolic disorder, and also an important cause of cardiovascular (CV) diseases (CVDs). Subclinical inflammation, observed in patients with type 2 DM (T2DM), cannot be considered the sole or primary cause of T2DM in the absence of classical risk factors, but it represents an important mechanism that serves as a bridge between primary causes of T2DM and its manifestation. Progress has been made in the identification of effective strategies to prevent or delay the onset of T2DM. It is important to identify those at increased risk for DM by using specific biomarkers. Inflammatory markers correlate with insulin resistance (IR) and glycoregulation in patients with DM. Also, several inflammatory markers have been shown to be useful in assessing the risk of developing DM and its complications. However, the intertwining of pathophysiological processes and the not-quite-specificity of inflammatory markers for certain clinical entities limits their practical use. In this review we consider the advantages and disadvantages of various inflammatory biomarkers of DM that have been investigated to date as well as possible future directions. Key features of such biomarkers should be high specificity, non-invasiveness and cost-effectiveness.

Insight Into The Molecular Basis Of The Anti‑Hyperglycemic Activity Of Ra‑3 In Type 2 Diabetic Rats And Its Cardioprotective Potential In Cultured Cardiomyoblasts

Metabolism ◽  
2021 ◽  
Vol 116 ◽  
pp. 154646
Author(s):  
R.A. Mosa ◽  
S.E. Mabhida ◽  
N.F. Sangweni ◽  
P.V. Dludla ◽  
A.R. Opoku ◽  
...  
Keyword(s):  
Molecular Basis ◽  
Diabetic Rats ◽  
Type 2 Diabetic ◽  
Insight Into

scholarly journals Brain sonography insight into the midbrain and basal ganglia in myotonic dystrophy type 2

2015 ◽  
Vol 357 ◽  
pp. e343
Author(s):  
V. Rakocevic-Stojanovic ◽  
S. Peric ◽  
D. Savic-Pavicevic ◽  
J. Pesovic ◽  
D. Lavrnic ◽  
...  
Keyword(s):  
Basal Ganglia ◽  
Myotonic Dystrophy ◽  
Myotonic Dystrophy Type ◽  
Myotonic Dystrophy Type 2 ◽  
Brain Sonography ◽  
Insight Into
Sign in / Sign up

Export Citation Format

Share Document